source
- Atea’s hepatitis C combo matches Gilead’s Epclusa in phase 3 trialBoston-based biotech Atea Pharmaceuticals reported that its once-daily hepatitis C combination of bemnifosbuvir and ruzasvir performed on par with Gilead's Epclusa in a pivotal phase 3 study. The…
- Eli Lilly climbs to top of Norstella’s Pipeline-to-Patient Productivity Index, beating 24 peersEli Lilly has risen to the top of Norstella’s inaugural Pipeline-to-Patient Productivity Index, a new benchmark that rates large global biopharma firms on research productivity, market access and c…